Ed Cappabianca
Plus aucun poste en cours
Profil
Ed Cappabianca was the founder and had founded EnXray Ltd.
in 2012, where he held the title of Chief Executive Officer & Director.
He also worked as President, Chief Executive Officer & Director at AmpliPhi Biosciences Corp.
In terms of education, he received an undergraduate degree from the University of Virginia and an MBA from the University of Pennsylvania.
Anciens postes connus de Ed Cappabianca
| Sociétés | Poste | Fin |
|---|---|---|
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | President | - |
EnXray Ltd.
 EnXray Ltd. Information Technology ServicesTechnology Services EnXray Ltd. operates as a medical technology company. Its technology includes low energy x-rays, radiation sterilization and lexr benefits. The company was founded by Edward cappabianca in 2012 and is headquartered in Liverpool, the United Kingdom. | Fondateur | - |
Formation de Ed Cappabianca
| University of Virginia | Undergraduate Degree |
| University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
EnXray Ltd.
EnXray Ltd. Information Technology ServicesTechnology Services EnXray Ltd. operates as a medical technology company. Its technology includes low energy x-rays, radiation sterilization and lexr benefits. The company was founded by Edward cappabianca in 2012 and is headquartered in Liverpool, the United Kingdom. | Technology Services |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
